Metastatic Urothelial Carcinoma Clinical Trials

15 studies are recruiting for metastatic urothelial carcinoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma

   A Randomized, Open-Label, Multicenter, Phase 2/3 Clinical Study of Ivonescimab in Combination with Enfortumab Vedotin vs Pembrolizumab in Combination with Enfortumab Vedotin in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma (HARMONi-GU1)

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Research Site, Los Angeles, California

   Locations

   7 in total

   Run by

   Summit Therapeutics

   See if you can join NCT07815665 on ClinicalTrials.gov

2. Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

   This phase I trial tests the safety, side effects, best dose, and effectiveness of emavusertib (CA-4948) in combination with pembrolizumab in treating patients with urothelial cancer that has spread from where it first started to other places in the body (metastatic) and that has a resistance to PD…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope Comprehensive Cancer Center, Duarte, California

   Locations

   11 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06439836 on ClinicalTrials.gov

3. A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

   This phase III trial compares the effectiveness of pembrolizumab and sacituzumab govitecan-hziy to standard of care in treating patients with urothelial cancer that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread to other places in the body (metastatic). Immunothera…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Cancer Center at Saint Joseph's, Phoenix, Arizona

   Locations

   161 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06524544 on ClinicalTrials.gov

4. Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

   This phase I/II trial tests the safety and tolerability of an experimental personalized vaccine when given by itself and with pembrolizumab in treating patients with solid tumor cancers that have spread to other places in the body (advanced). The experimental vaccine is designed target certain prot…

   Stage

   Phase 1

   Ages

   16 and older

   Site

   Mayo Clinic in Florida, Jacksonville, Florida

   Run by

   Mayo Clinic

   See if you can join NCT05269381 on ClinicalTrials.gov

5. Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

   The purpose of this study is to evaluate the safety and tolerability of an investigational drug called GB-4362 when it is given together with enfortumab vedotin and pembrolizumab in adults with advanced or metastatic urothelial cancer. GB-4362 is a monoclonal antibody designed to bind and neutraliz…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope, Duarte, California

   Locations

   10 in total

   Run by

   Generate Biomedicines

   See if you can join NCT07484022 on ClinicalTrials.gov

6. Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

   This phase II trial compares the impact of subcutaneous (SC) nivolumab given in an in-home setting to an in-clinic setting on cancer care and quality of life. Currently, most drug-related cancer care is conducted in clinic type centers or hospitals which may isolate patients from family, friends an…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Mayo Clinic in Florida, Jacksonville, Florida

   Run by

   Mayo Clinic

   See if you can join NCT06265285 on ClinicalTrials.gov

7. A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma

   The purpose of this study is to see how results of nerve tests change in people with urothelial cancer who receive treatment with enfortumab vedotin (EV)

   Stage

   Not phased

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT07390617 on ClinicalTrials.gov

8. Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer

   This phase I/Ib trial seeks to find out the best dose, possible benefits and/or side effects of cabozantinib in combination with enfortumab vedotin in treating urothelial cancer that has spread to nearby tissues and lymph nodes (locally advanced) or other parts of the body (metastatic). Cabozantini…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia

   Run by

   Emory University

   See if you can join NCT04878029 on ClinicalTrials.gov

9. Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial

   This trial compares cryoablation combined with stereotactic body radiation therapy to stereotactic body radiation therapy alone to see how well they work in treating patients with pain from cancer that has spread to the bones (bone metastases). Bone is a common site of metastasis in advanced cancer…

   Stage

   Not phased

   Ages

   18 and older

   Site

   M D Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT04693377 on ClinicalTrials.gov

10. Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma

    This is a single-arm, open-label, non-randomized Phase II trial evaluating the efficacy of induction therapy with enfortumab vedotin (EV) plus pembrolizumab (P) for 18 weeks (6 cycles), followed by maintenance pembrolizumab in treatment-naïve patients with metastatic urothelial carcinoma (mUC). App…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania

    Run by

    Fox Chase Cancer Center

    See if you can join NCT07221942 on ClinicalTrials.gov

11. An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy

    The purpose of this study is to understand the metabolism of cancers involving the kidney, including renal cell carcinomas and urothelial cell carcinomas, and how kidney cancers use different types of fuel to support tumor growth. This study uses specially labeled nutrient tracers of compounds norm…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Texas Southwestern Medical Center, Dallas, Texas

    Run by

    University of Texas Southwestern Medical Center

    See if you can join NCT04623502 on ClinicalTrials.gov

12. Sacituzumab Govitecan Plus EV in Metastatic UC

    Phase I of this research study will assess what doses of Sacituzumab Govitecan and Enfortumab Vedotin can be safely combined in the treatment of metastatic urothelial carcinoma (mUC). In Phase II of the study, patients in one of the two cohorts will receive Sacituzumab Govitecan, Enfortumab Vedotin…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Dana Farber Cancer Institute, Boston, Massachusetts

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT04724018 on ClinicalTrials.gov

13. A Study of NX-1607 in Adults With Advanced Malignancies

    This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Southern California, Los Angeles, California

    Locations

    17 in total

    Run by

    Nurix Therapeutics, Inc.

    See if you can join NCT05107674 on ClinicalTrials.gov

14. Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors

    Patients with solid tumors that have high expression levels of EphrinB2 are treated with regimens that include EphrinB2 inhibitor, sEphB4-HSA. The primary objective of this study is to demonstrate additive therapeutic benefit for sEphB4-HSA. The secondary objectives are to determine whether the sEp…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Sarcoma Oncology Center, Santa Monica, California

    Run by

    Vasgene Therapeutics, Inc

    See if you can join NCT06493552 on ClinicalTrials.gov

15. CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

    This phase II trial tests how well CPI-613 (devimistat) in combination with hydroxychloroquine (HCQ) and 5-fluorouracil (5-FU) or gemcitabine works in patients with solid tumors that may have spread from where they first started to nearby tissue, lymph nodes, or distant parts of the body (advanced)…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Northwestern University, Chicago, Illinois

    Run by

    Northwestern University

    See if you can join NCT05733000 on ClinicalTrials.gov